Faster recovery and reduced paracetamol use – a meta-analysis of EPs 7630 in children with acute respiratory tract infections

Table 1 Main characteristics of eligible trials

Indication	Study, reference	Treatment duration, daily dose	Maximum daily paracetamol dose allowed^%	Primary efficacy outcome measure ⁺	Number of patients^#
Indication	Study, reference	Treatment duration, daily dose	Maximum daily paracetamol dose allowed^%	Primary efficacy outcome measure ⁺	EPs 7630	Placebo
Acute tonsillopharyngitis	A Timen et al., 2015 [60]	6 days: Day 1–2: 20 drops hourly while awake, Day 3–6: 3 × 20 drops	Up to 3 × 500 mg on days 0 to day 4	Response: TSS (7 symptoms) ≤ 4 points at day 4	40	38
	B Berezhnoi et al., 2016 [55]	6 days: 3 × 20 drops		TSS (5 symptoms): difference baseline – day 4	60	64
	C Bereznoy et al., 2003 [56]	6 days: 3 × 20 drops		TSS (5 symptoms): difference baseline – day 4	73	70
Acute bronchitis	D Kamin et al., 2010a [58]	7 days: Age ≤ 6: 3 × 10 drops Age 7–10: 3 × 20 drops	Age ≤ 6: 3 × 250 mg Age 7–10: 3 × 500 mg	BSS: difference baseline – day 7	25^§	24^§
	E Kamin et al., 2010b [59]	7 days: 3 × 20 mg (tablets)	3 × 500 mg	BSS: difference baseline – day 7	32^§&	31^§
	F Kamin et al., 2012 [57]	7 days: Age ≤ 6: 3 × 10 drops, Age 7–10: 3 × 20 drops	Age ≤ 6: 3 × 250 mg Age 7–10: 3 × 500 mg	BSS: difference baseline – day 7	35^§	31^§

^% Only allowed on days with fever ≥38.5 °C
⁺ TSS Tonsillopharyngitis Symptom Score (total score), BSS Bronchitis Symptom Score (total score)
^# Primary efficacy analysis data set (full analysis set)
^§ Only children 6–10 years of age
^& Only children randomised to 3 × 20 mg/day

ISSN: 1471-2431